TickerTalks
Browse all tickers →
TickerTalks›$SLP
SLSLP

Simulations Plus, Inc.

$SLP·$369M·Medical - Healthcare Information Services·Healthcare
$18.24-0.1%YTD-0.8%1Y+0.9%
Mentions · last 7 days
0
Price updated 27m ago
SLSLP
Simulations Plus, Inc.$SLP
$18.24-0.05%0 posts
AI analysisFundamentalsVoices on X
Loading…

What it does

Plain-English summary of the business — what they sell and how they make money.

Simulations Plus, Inc. (SLP) is a worldwide developer of sophisticated software and services aimed at enhancing drug discovery and development processes. The company employs artificial intelligence and machine learning technologies to create tools for modeling, simulation, and predicting molecular characteristics. Its operations are divided into four main business units: Simulations Plus, Cognigen, DILIsym, and Lixoft. Among its diverse software offerings are GastroPlus, which models the absorption and drug interactions of compounds in both human and animal subjects, as well as DDDPlus and MembranePlus for various simulations. The company also provides a range of products built on mechanistic and mathematical models, such as its quantitative systems pharmacology software like DILIsym, NAFLDsym, IPFsym, RENAsym, and MITOsym. Furthermore, Simulations Plus offers the ADMET Predictor, a chemistry-focused computer program that forecasts molecular properties from structural inputs, alongside MedChem Designer, MonolixSuite, and PKPlus for additional modeling and simulation needs. Beyond software, the company extends its expertise through various services, including contract research for population modeling and simulation, specialized training and consultation to advance pharmacometrics studies, and clinical-pharmacology consulting to aid in regulatory submissions. Simulations Plus serves a broad spectrum of clients globally, including pharmaceutical, biotechnology, agrochemical, cosmetic, and food companies, as well as academic institutions and regulatory bodies. The company was founded in 1996 and maintains its headquarters in Lancaster, California.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Healthcare Information Services sits in its cycle right now — and what that implies for $SLP.

Medical - Healthcare Information Services · Healthcare

Agentic AI is entering life sciences commercialization — VEEV's 'agentic commercial' CRM framing converts AI from feature to platform pricing, while TEM's oncology AI platform and pharma data licensing confirm AI becoming the analytical infrastructure layer for clinical research and drug development.

Industry benchmark

9-name peer basket
+3.9%YTD
+31.8%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-5.9How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-47.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-83.5%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
6.2%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
4.6Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-49.3%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
62.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026Apr 9, 2026$0.35$0.27+29.6%
Q4 2025Jan 8, 2026$0.13$0.18-27.8%
Q3 2025Dec 1, 2025$0.10$0.100.0%
Q2 2025Jul 14, 2025$0.45$0.26+73.1%
Next earningsThu, Jul 9·consensus EPS $0.23

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$24.3M+8.3%66.5%23.2%$0.23$6.4M
Q1 FY26$18.4M-2.7%59.1%3.9%$0.03$3.3M
Q4 FY25$17.5M-6.5%56.4%3.8%$-0.03$5.3M
Q3 FY25$20.4M+9.8%64.0%-365%$-3.35$7.8M

Forward consensus

5-year forecast · up to 4 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$81.8M$81.4M – $82.2M$0.86$0.85 – $0.884
FY27$86.5M$85.3M – $87.8M$0.91$0.90 – $0.934
FY28$92.6M$90.7M – $94.5M$1.06$1.04 – $1.081
FY29$103.4M$102.2M – $104.7M$1.28$1.26 – $1.301
FY30$117.1M$115.7M – $118.5M$1.56$1.54 – $1.581

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.2.4×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.72%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+19.5%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+16.1%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 16.7M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today6.1% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.325-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJun 16Jill Fiedler-kellyPresident7.3K sh$134KSellJun 15Jill Fiedler-kellyPresident1.1K sh$17KSellJun 3Dibella John Anthony IiChief Revenue Officer1.0K sh$17KSellJun 1Walter S WoltoszDirector15.0K sh$261KSellMay 11Jill Fiedler-kellyPresident1.0K sh$17KSellMay 4Dibella John Anthony IiChief Revenue Officer1.0K sh$15KSellMay 4Walter S WoltoszDirector15.0K sh$227KSellApr 15Dibella John Anthony IiChief Revenue Officer1.0K sh$13K
+ 13 other (8 awards · 5 exempts) in window

See when $SLP insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Simulations Plus, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – SLPbusinesswire.com·1d agoSimulations Plus Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Simulations Plus, Inc. - SLPbusinesswire.com·1d agoSHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Simulations Plus, Inc. (NASDAQ: SLP)gurufocus.com·1d agoSHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Simulations Plus, Inc. (NASDAQ: SLP)prnewswire.com·1d agoSimulations Plus (SLP) Investigation: Investors Who Suffered Losses Encouraged to Contact Johnson Fistelglobenewswire.com·2d ago

More in Medical - Healthcare Information Services

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$TEM$VEEV$BTSG$TXG$HCAT$SDGR$OMCL$PGNY
Voices on X · top 2 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport